ATE220919T1 - Zusammensetzungen zur minimierung des uterustrophischen effekts von tamoxifen und dessen analogen - Google Patents

Zusammensetzungen zur minimierung des uterustrophischen effekts von tamoxifen und dessen analogen

Info

Publication number
ATE220919T1
ATE220919T1 AT95306539T AT95306539T ATE220919T1 AT E220919 T1 ATE220919 T1 AT E220919T1 AT 95306539 T AT95306539 T AT 95306539T AT 95306539 T AT95306539 T AT 95306539T AT E220919 T1 ATE220919 T1 AT E220919T1
Authority
AT
Austria
Prior art keywords
alkyl
radical
formula
compound
lower alkyl
Prior art date
Application number
AT95306539T
Other languages
English (en)
Inventor
Henry Uhlman Bryant
Steven Anthony Fontana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE220919T1 publication Critical patent/ATE220919T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95306539T 1994-09-20 1995-09-18 Zusammensetzungen zur minimierung des uterustrophischen effekts von tamoxifen und dessen analogen ATE220919T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/308,904 US5554628A (en) 1994-09-20 1994-09-20 Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs

Publications (1)

Publication Number Publication Date
ATE220919T1 true ATE220919T1 (de) 2002-08-15

Family

ID=23195869

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95306539T ATE220919T1 (de) 1994-09-20 1995-09-18 Zusammensetzungen zur minimierung des uterustrophischen effekts von tamoxifen und dessen analogen

Country Status (16)

Country Link
US (1) US5554628A (de)
EP (1) EP0702961B1 (de)
JP (1) JPH10506111A (de)
KR (1) KR970705999A (de)
AT (1) ATE220919T1 (de)
AU (1) AU692932B2 (de)
CA (1) CA2200205A1 (de)
CZ (1) CZ82097A3 (de)
DE (1) DE69527480D1 (de)
FI (1) FI971155A7 (de)
HU (1) HUT77954A (de)
MX (1) MX9702037A (de)
NO (1) NO971229L (de)
NZ (1) NZ294176A (de)
RU (1) RU2158589C2 (de)
WO (1) WO1996009051A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
CA2298651A1 (en) * 1997-08-07 1999-02-18 Jeffrey Alan Dodge 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity
EP1113007A1 (de) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
ATE448215T1 (de) * 2004-01-22 2009-11-15 Lilly Co Eli Selektive östrogen-rezeptor-modulatoren
WO2012091425A2 (ko) * 2010-12-27 2012-07-05 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
KR101311534B1 (ko) * 2010-12-27 2013-09-25 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 치료 또는 예방용 조성물
WO2012119010A2 (en) * 2011-03-01 2012-09-07 Indiana University Research And Technology Corporation Materials for inhibiting aromatase and method of using the same to diagnose, treat and monitor breast cancer
WO2013134230A1 (en) * 2012-03-05 2013-09-12 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
CZ305571B6 (cs) * 2014-01-29 2015-12-16 Smart Brain s.r.o. Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
EP0002097B1 (de) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalken-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
GB2097788B (en) * 1981-04-03 1985-04-24 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4329344A1 (de) * 1993-08-27 1995-03-02 Schering Ag Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Also Published As

Publication number Publication date
CZ82097A3 (en) 1997-08-13
EP0702961A2 (de) 1996-03-27
CA2200205A1 (en) 1996-03-28
HUT77954A (hu) 1998-12-28
AU692932B2 (en) 1998-06-18
FI971155L (fi) 1997-03-19
KR970705999A (ko) 1997-11-03
NO971229D0 (no) 1997-03-17
RU2158589C2 (ru) 2000-11-10
FI971155A0 (fi) 1997-03-19
NZ294176A (en) 1999-10-28
DE69527480D1 (de) 2002-08-29
FI971155A7 (fi) 1997-03-19
NO971229L (no) 1997-03-17
JPH10506111A (ja) 1998-06-16
AU3686295A (en) 1996-04-09
US5554628A (en) 1996-09-10
WO1996009051A1 (en) 1996-03-28
EP0702961B1 (de) 2002-07-24
EP0702961A3 (de) 1999-11-10
MX9702037A (es) 1997-06-28

Similar Documents

Publication Publication Date Title
DK0703228T3 (da) Naphthylforbindelser, mellemprodukter, fremgangsmåder, sammensætninger, som indeholder disse
BR9811042A (pt) Composto, formulação farmacêutica, uso de um composto, e, processos para o tratamento de distúrbios no sistema nervoso central e/ou de incontinência urinária, vasoespasmos e controle do crescimento de tumores e para a preparação do composto
AR003930A1 (es) Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados
MX9600743A (es) Compuestos de naftilo, intermediarios y composiciones farmaceuticas a partir de los mismos y proceso para su preparacion.
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
GEP20053459B (en) New Thiadiazoles and Oxidiazoles and Their Use as Phosphodiesterase-7 Inhibitors
DE69527480D1 (de) Zusammensetzungen zur Minimierung des uterustrophischen Effekts von Tamoxifen und dessen Analogen
DE69628246D1 (de) Naphthyl- und Dihydronaphthylverbindungen als Arzneimittel
TW372969B (en) Pharmaceutical composition for minimizing bone loss
BR9812238A (pt) Composto, uso deste, processo para a preparação do mesmo, formulação farmacêutica, e, processos para o tratamento de distúrbios do sistema nervoso central e/ou incontinência urinária, ou vasoespasmo, ou para controle de crescimento de tumores, e para o tratamento de distúrbios mediados por 5-hidroxitriptamina
ATE207473T1 (de) Dihydronaphthalen- und naphthalenderivate, zwischenverbindungen, zusammensetzungen und deren herstellungsverfahren
AR036351A1 (es) Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas
RU97106107A (ru) Способ минимизации гистеротрофного эффекта тамоксифена и аналогов тамоксифена
YU34296A (en) Use a compounds for medicament obtaining and pharmaceutical composition thereof
TH27482A (th) วิธีสำหรับลดการสูญเสียกระดูก
TH27625A (th) วิธีการสำหรับลดการสูญเสียกระดูก

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties